Biostem Technologies

Biostem Technologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Biostem Technologies (BSEM) as of Oct 4, 2026 is 75.43 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 43.73 % — a change of 72.50% (higher).

FCF Conversion

75.43 %

YoY

72.50%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biostem Technologies is 2026 75.43 % . FCF Conversion Rate (FCF/EBITDA) of Biostem Technologies was 2025 43.73 % . It decreases by 72.50% higher compared to the previous year.

The Biostem Technologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
37.06 USD
Jan 1, 2018
50.81 USD
Jan 1, 2019
15.46 USD
Jan 1, 2020
24.34 USD
Jan 1, 2021
10.54 USD
Jan 1, 2022
26.58 USD
Jan 1, 2023
43.73 USD
Jan 1, 2024
75.43 USD
The Biostem Technologies FCF Conversion history
YEARFCF ConversionYoY
75.43 %+72.50%
43.73 %+64.51%
26.58 %+152.28%
10.54 %-56.71%
24.34 %+57.45%
15.46 %-69.58%
50.81 %+37.11%
37.06 %-39.16%
60.91 %-12.09%
69.29 %-91.29%
795.81 %—
Access this data via the Eulerpool API

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

FCF Conversion Rate (FCF/EBITDA) of Biostem Technologies is 75.43 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Biostem Technologies changed from 43.73 % to 75.43 %, representing a 72.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biostem Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Biostem Technologies

All Key Metrics — Biostem Technologies